about
Overview of the clinical efficacy of investigational anticancer drugs.New approaches in the immunotherapy of haematological malignancies.Cytokines as clinical adjuvants: how far are we?Monocyte-derived dendritic cells in chronic lymphocytic leukemia.Tracking of dendritic cell migration into lymph nodes using molecular imaging with sodium iodide symporter and enhanced firefly luciferase genes.Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy.Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study.Immunology and immunotherapy approaches for prostate cancer.Multimodality Imaging of Bone Marrow-Derived Dendritic Cell Migration and Antitumor ImmunityDendritic cell immunotherapy for HIV infection: from theory to reality.Role of tyrosine kinase inhibitors in tumor immunology.RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma.Autologous dendritic cell based adoptive immunotherapy of patients with colorectal cancer-A phase I-II study.Maturation of human monocyte-derived dendritic cells (MoDCs) in the presence of prostaglandin E2 optimizes CD4 and CD8 T cell-mediated responses to protein antigens: role of PGE2 in chemokine and cytokine expression by MoDCs.CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides.Increased tumor-specific CD8+ T cell induction by dendritic cells matured with a clinical grade TLR-agonist in combination with IFN-gamma.
P2860
Q35067125-F590E9DD-1D92-4C6C-A549-A1394095DEE0Q35106657-04A32D4C-4536-445A-B37C-6D8962591CB1Q35192213-7394B54F-12B0-478E-9C4A-08E76A842484Q35210402-D567D700-B367-4A8E-AAF0-8542B42FBD38Q35605392-4A511325-5B1B-4851-96AB-D6140E126677Q36673517-0F2626B1-CB54-4632-8326-E62A9B3C1DFBQ36695932-D2AE3156-73D6-4457-94A5-BBC15442D70AQ36786512-CFBE1B2E-A876-45B3-A64E-2FCC30D2398DQ37648949-36CD7900-DA30-49B1-A321-4C77F45A0E54Q37773251-29C2F2F8-0829-4F64-901F-972ABA2E0340Q37822748-ECD5DC8F-A72A-4D8D-A664-548F349A48F6Q40002875-A944F4B1-51D4-48A3-877F-1EABEC521AA5Q44437073-AA3FC34F-0052-4562-9B29-A9C42862B99BQ46816706-C38E085B-5B4C-4B0E-87CF-086D7DE3B118Q48371221-4E45B6D0-E17B-4287-A6A1-DAB704DAC129Q51059137-72AFB937-E351-4578-AA95-8503C367F79B
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The use of dendritic cells in cancer therapy.
@ast
The use of dendritic cells in cancer therapy.
@en
The use of dendritic cells in cancer therapy.
@nl
type
label
The use of dendritic cells in cancer therapy.
@ast
The use of dendritic cells in cancer therapy.
@en
The use of dendritic cells in cancer therapy.
@nl
prefLabel
The use of dendritic cells in cancer therapy.
@ast
The use of dendritic cells in cancer therapy.
@en
The use of dendritic cells in cancer therapy.
@nl
P2093
P1433
P1476
The use of dendritic cells in cancer therapy.
@en
P2093
P304
P356
10.1016/S1470-2045(00)00389-2
P50
P577
2001-06-01T00:00:00Z